Clover Health stock falls 2.19 percent as profit turns positive

Clover Health stock (CLOV) was trading at USD 4.47 on Nasdaq on September 24, 2026, down USD 0.10 or 2.19 percent from the previous close. The latest operating picture is more constructive: Q2 2026 revenue reached USD 743.2 million, up 55.6 percent year over year.

Q2 revenue reached USD 743.2 million

According to Yahoo Finance, Clover Health reported Q2 2026 results on August 5, 2026. Revenue rose from USD 477.6 million in the same quarter of 2025 to USD 743.2 million, while Medicare Advantage membership increased 48 percent to 157,309.

The comparison is important because growth came with a stronger earnings profile. Consolidated gross profit rose 53.6 percent to USD 153.0 million, and adjusted EBITDA increased 139.2 percent to USD 40.9 million from USD 17.1 million a year earlier.

Profit swings to USD 28 million

GAAP net income reached USD 28 million in Q2 2026, compared with a USD 10.6 million loss in Q2 2025. The USD 38.6 million year-over-year swing gives the revenue increase a direct bottom-line consequence.

Clover also raised its 2026 outlook after the quarter. The updated adjusted EBITDA range is USD 70 million to USD 85 million, compared with the previous USD 50 million to USD 70 million range, while GAAP net income guidance moved to USD 20 million to USD 35 million from USD 0 million to USD 20 million, according to Yahoo Finance.

Stock trades below its yearly high

The USD 4.47 Nasdaq price on September 24, 2026 stood 20.04 percent below Clover Health stock's 52-week high of USD 5.59. Its 52-week low was USD 1.58, leaving the share price 182.91 percent above that level.

Market capitalization was USD 2,316,608,629 at the same quote timestamp. For investors, the central comparison is now between a 2.19 percent daily decline and a Q2 operating profile that delivered 55.6 percent revenue growth, a USD 38.6 million profit swing and higher full-year guidance.